Syndax Pharmaceuticals stock forecast
Syndax Pharmaceuticals (1T3) Stock Forecast & Price Target
1T3 Analyst Ratings
1T3 Stock 12 Month Forecast
Average Price Target
€33.48▲(326.21% Upside)Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| David Dai | UBS | €30.10→€28.27 | buy | 259.87%Upside | Assigned | 11/20/26 | ||
| Andres Y. Maldonado | H.C. Wainwright | €32.83 | buy | 317.91%Upside | Reiterated | 11/05/26 | ||
| Stephen Willey | Stifel Nicolaus | €36.48 | buy | 364.35%Upside | Assigned | 11/05/26 | ||
| B. Riley Securities | €30.10 | buy | 283.09%Upside | Initiated | 11/04/26 | |||
| Etzer Darout | Barclays | €33.74 | buy | 329.52%Upside | Reiterated | 11/03/26 | ||
| Jason Zemansky | Bank of America Securities | €20.98 | buy | 167.00%Upside | Reiterated | 11/02/26 | ||
| Yigal Nochomovitz | Citi | €51.98 | buy | 561.70%Upside | Reiterated | 11/02/26 | ||
| Anupam Rama | J.P. Morgan | €40.13→€36.48 | buy | 364.35%Upside | Reiterated | 08/11/26 | ||
| Phil Nadeau | TD Cowen | ― | buy | ― | Reiterated | 08/04/26 | ||
| Corinne Johnson | Goldman Sachs | €31.01 | buy | 294.70%Upside | Reiterated | 07/14/26 | ||
| Bradley Canino | Guggenheim | €28.27 | buy | 259.87%Upside | Reiterated | 07/14/26 | ||
| Faisal Khurshid | Jefferies | €36.48→€33.74 | buy | 329.52%Upside | Reiterated | 05/01/26 | ||
| Salim Syed | Mizuho Securities | €41.04→€39.22 | buy | 399.17%Upside | Reiterated | 03/30/26 | ||
| Justin Zelin | BTIG | €51.07 | buy | 550.09%Upside | Reiterated | 01/02/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| David DaiUBS | BuyAssigned€30.10→€28.27 | 11/20/26 | 259.87%Upside | ||
| Andres Y. MaldonadoH.C. Wainwright | BuyReiterated€32.83 | 11/05/26 | 317.91%Upside | ||
| Stephen WilleyStifel Nicolaus | BuyAssigned€36.48 | 11/05/26 | 364.35%Upside | ||
| BuyInitiated€30.10 | 11/04/26 | 283.09%Upside | |||
| Etzer DaroutBarclays | BuyReiterated€33.74 | 11/03/26 | 329.52%Upside | ||
| Jason ZemanskyBank of America Securities | BuyReiterated€20.98 | 11/02/26 | 167.00%Upside | ||
| Yigal NochomovitzCiti | BuyReiterated€51.98 | 11/02/26 | 561.70%Upside | ||
| Anupam RamaJ.P. Morgan | BuyReiterated€40.13→€36.48 | 08/11/26 | 364.35%Upside | ||
| Phil NadeauTD Cowen | BuyReiterated | 08/04/26 | ― | ||
| Corinne JohnsonGoldman Sachs | BuyReiterated€31.01 | 07/14/26 | 294.70%Upside | ||
| Bradley CaninoGuggenheim | BuyReiterated€28.27 | 07/14/26 | 259.87%Upside | ||
| Faisal KhurshidJefferies | BuyReiterated€36.48→€33.74 | 05/01/26 | 329.52%Upside | ||
| Salim SyedMizuho Securities | BuyReiterated€41.04→€39.22 | 03/30/26 | 399.17%Upside | ||
| Justin ZelinBTIG | BuyReiterated€51.07 | 01/02/26 | 550.09%Upside |
Best Analysts Covering Syndax Pharmaceuticals
Copying Justin Zelin's trades and holding each position for 3 Months would result in 52.63% of your transactions generating a profit, with an average return of +6.64% per trade.
Copying Anupam Rama's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of -0.52% per trade.
Copying Anupam Rama's trades and holding each position for 2 Years would result in 19.05% of your transactions generating a profit, with an average return of -23.35% per trade.
1T3 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 18 | 18 | 14 | 14 | 14 |
| Buy | 6 | 7 | 7 | 2 | 0 |
| Hold | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 24 | 25 | 21 | 16 | 15 |
In the current month, 1T3 has received 14 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 1T3 average Analyst price target in the past 3 months is 33.48.
1T3 Financial Forecast
1T3 Earnings Forecast
Next quarter’s earnings estimate for 1T3 is -EUR 0.44 with a range of -EUR 0.56 to -EUR 0.18. The previous quarter’s EPS was -EUR 0.50. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
1T3 Sales Forecast
Next quarter’s sales forecast for 1T3 is EUR 86.79M with a range of EUR 80.15M to EUR 116.62M. The previous quarter’s sales results were EUR 75.97M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

